ArticleScientific reports2026

Brolucizumab versus aflibercept in treating exudative age-related macular degeneration: a 12-month pro re nata regimen.

Wataru Kikushima et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.